BSECompany Update29 Jul 2026
Dr Reddys Laboratories Ltd
Clarification- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Dr Reddy's Laboratories Ltd clarifies a news article published in Business Standard regarding the company's antibiotic getting Thailand approval six months after US nod. The company confirms the accuracy of the news and states that it does not constitute a material event or information requiring disclosure under Regulation 30 of SEBI Listing Regulation.
BSECompany UpdateResults28 Jul 2026
Dr Reddys Laboratories Ltd
Transcript of Earnings call recording
Dr Reddy's Laboratories Ltd reported Q1FY27 revenue decline of 5.6% YoY and EBITDA margin of 12.5%, impacted by lower lenalidomide revenues and provision for semaglutide API related challenges.
BSECompany UpdateRegulatory28 Jul 2026
Dr Reddys Laboratories Ltd
The Exchange has sought clarification from Dr Reddys Laboratories Ltd with reference to the media report appearing on https://www.business-standard.com dated July 28, 2026, (Link:https://www.business-standard.com/companies/news/dr-reddys-first-in-class-gonorrhoea-drug-gets-thailand-approval-after-us-nod-126072700632_1.html) ....
Dr Reddys Laboratories Ltd has been asked by the exchange to clarify a media report regarding the company's first-in-class gonorrhoea drug receiving approval in Thailand after receiving US nod.
BSECompany UpdateMgmt Change23 Jul 2026
Dr Reddys Laboratories Ltd
Disclosure under Regulation 30 of SEBI (LODR) Regulation, 2015
Dr. Reddy's Laboratories Ltd. has announced the re-appointment of Dr. K P Krishnan as an Independent Director for a second term of five consecutive years, and the appointment of Mr. Srikanth Velamakanni as an Independent Director for a term of five consecutive years. The company has also appointed M/s Deloitte Haskins & Sells, LLP, Chartered Accountants as Statutory Auditors for a term of five consecutive years.
BSEAGM/EGMResults23 Jul 2026
Dr Reddys Laboratories Ltd
Scrutinizer''s Report
Dr. Reddy's Laboratories Ltd. has announced the outcome of its 42nd Annual General Meeting (AGM), which was held through video conferencing on July 23, 2026. The meeting was attended by 86 members holding 22,25,59,764 shares. The AGM proceedings were conducted in compliance with the applicable Circulars issued by the Ministry of Corporate Affairs (MCA) and Securities and Exchange Board of India (SEBI). The company's Integrated Annual Report for FY2025-26, containing the Notice of the 42nd AGM and the Auditor's Report, was circulated to the members through electronic mode.
BSEAGM/EGMResults23 Jul 2026
Dr Reddys Laboratories Ltd
Outcome of 42nd Annual General Meeting
Dr. Reddy's Laboratories Ltd. held its 42nd Annual General Meeting (AGM) on July 23, 2026, through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The meeting was conducted in compliance with the General Circular issued by the Ministry of Corporate Affairs (MCA) and circular issued by the Securities and Exchange Board of India (SEBI). The requisite quorum was present, and the meeting was called to order. The Chairman extended a warm welcome to all members and other participants. The Company Secretary informed the members that the meeting is being held through VC/OAVM in compliance with the applicable Circulars issued by the MCA and SEBI. The Integrated Annual Report for FY2025-26 containing the Notice of the 42nd AGM and the Auditor's Report was circulated to the members through electronic mode. The Notice convening the meeting and the Auditor's Report are taken as read. The Chairman delivered his speech followed by the address by the Co-Chairman and Managing Director.
BSECompany UpdateResults23 Jul 2026
Dr Reddys Laboratories Ltd
Copy of newspaper publication
Dr Reddys Laboratories Ltd has published unaudited financial results for the quarter ended June 30, 2026, in Business standard and Andhra Prabha newspapers.
BSECompany UpdateResults23 Jul 2026
Dr Reddys Laboratories Ltd
Intimation of Earnings call recordings
Dr Reddys Laboratories Ltd has made available the audio recordings of its earnings call for the quarter ended June 30, 2026, as per Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
BSECompany Update▲ PositiveResults22 Jul 2026
Dr Reddys Laboratories Ltd
Copy of Investor Presentation
Dr. Reddy's Laboratories Ltd. has announced its unaudited financial results for Q1 FY27, with a healthy double-digit base business growth and an EBITDA margin of 15.4% before the semaglutide-related impact. The company has also made significant progress across its strategic priorities, including the launch of new products and partnerships.
BSECompany Updateemployee_benefits22 Jul 2026
Dr Reddys Laboratories Ltd
Grant of Employee Stock Options
Dr. Reddy's Laboratories Ltd. has informed about the grant of employee stock options under the Employees Stock Option Scheme, 2018. The company has approved the grant of 15,933 stock options to eligible employees at a price of Rs. 1,206 per share, with 100% vesting at the end of 3 years.
BSECompany UpdateMgmt Change22 Jul 2026
Dr Reddys Laboratories Ltd
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Dr Reddy's Laboratories Ltd has announced the appointment of Dr Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, effective July 22, 2026. The company has also appointed M/s Deloitte Haskins & Sells, LLP as Independent Registered Public Accounting Firm for a term of five consecutive years.
BSEResultResults22 Jul 2026
Dr Reddys Laboratories Ltd
Unaudited Financial results for the quarter ended June 30, 2026
Dr. Reddy's Laboratories Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with revenues of Rs. 80,705 million, gross profit of Rs. 37,540 million, and a net profit of Rs. 4,348 million. The company has also announced the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, and the appointment of M/s Deloitte Haskins & Sells, LLP as the Independent Registered Public Accounting Firm.
BSEBoard Meeting▲ PositiveResults22 Jul 2026
Dr Reddys Laboratories Ltd
Outcome of Board Meeting held on July 22, 2026
Dr Reddy's Laboratories Ltd announced unaudited financial results for the quarter ended June 30, 2026, with revenues of Rs 80,705 million, gross profit of Rs 37,540 million, and profit for the period of Rs 4,348 million. The company also announced the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, and the appointment of M/s Deloitte Haskins & Sells, LLP as Independent Registered Public Accounting Firm.
BSEInsider Trading / SASTResults22 Jun 2026
Dr Reddys Laboratories Ltd
Intimation regarding Closure of Trading window
Dr. Reddy's Laboratories Ltd. announced that its Board of Directors will convene on July 22, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. In accordance with SEBI insider trading regulations, the trading window for the company's securities will be closed from June 24, 2026, until July 24, 2026. This closure is standard practice ahead of financial result announcements to prevent insider trading.
BSEBoard Meeting22 Jun 2026
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/07/2026 ,inter alia, to consider and approve the Un-audited Standalone ....
Dr. Reddy's Laboratories Ltd. announced that its Board of Directors will convene on July 22, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. This is a routine regulatory filing ahead of the quarterly earnings release. Concurrently, the trading window for the company's securities will remain closed from June 24, 2026, until July 24, 2026, for designated persons.